Terumo entered into a definitive agreement to acquire OrganOx and its organ preservation technology.
Tokyo-based Terumo agreed to acquire all outstanding OrganOx shares for approximately $1.5 billion. Upon completion of the transaction, OrganOx becomes a wholly owned subsidiary of Terumo.
Terumo Cardiovascular makes a long-running line of commercially available heart-lung machines used in heart surgeries and was a key driver behind Terumo’s 12% revenue growth last year. Terumo aims to leverage its MedTech expertise in combination with OrganOx’s advanced capabilities to deliver innovative organ preservation devices globally.
Related: HistoSonics has majority stake acquired for $2.25bn by investor syndicate
This marks the second major acquisition of an organ preservation technology company within the last year, after Getinge bought Paragonix for $477 million.
Terumo aims to broaden access for patients in need of transplants and address key challenges in organ transplantation. That includes improving organ utilization rates, enabling the use of marginal donor organs, enhancing post-transplant outcomes and reducing the burden on healthcare professionals through minimizing nighttime and emergency procedures.
“We are thrilled to welcome OrganOx—a leading innovator in organ preservation technology—into the Terumo Group, marking our entry into the organ transplantation field,” said Hikaru Samejima, CEO of Terumo Corporation. “Organ transplantation represents a last resort for patients with limited treatment options, and addressing the unmet needs in this area carries significant social value. Donated organs are an extremely precious medical resource, and OrganOx’s mission to deliver transplantable organs in optimal condition deeply resonates with our unwavering commitment to patients — our promise.
“Together with OrganOx, we will strive to provide innovative solutions to tackle the diverse challenges surrounding organ transplantation.”
“This transaction represents an important milestone for OrganOx and its shareholders,” said Craig Marshall, Chief Executive Officer of OrganOx. “We look forward to continuing our rich history of collaboration with Terumo to continue harnessing our collective innovations to improve patient care.”
